220 related articles for article (PubMed ID: 29952306)
1. The DRAGON study: biologic DRug survivAl in PortuGuese psOriasis patieNts.
Torres T; Filipe P; Basto AS; Fernandes JC; Ferreira A; Rosmaninho A; Pereira M; Leite L; Navarro JL; Coelho R; Ferreira P; Selores M
Eur J Dermatol; 2018 Oct; 28(5):685-687. PubMed ID: 29952306
[No Abstract] [Full Text] [Related]
2. Effectiveness of sequential use of biologics in the treatment of moderate to severe psoriasis in real world Canadian academic clinical practice: A cohort study.
Qiang JK; Shahbaz A; Kim W; Marinas J; Greaves S; Yeung J
J Am Acad Dermatol; 2016 Jan; 74(1):176-7. PubMed ID: 26702799
[No Abstract] [Full Text] [Related]
3. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
Ross C; Marshman G; Grillo M; Stanford T
Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697
[TBL] [Abstract][Full Text] [Related]
4. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
[TBL] [Abstract][Full Text] [Related]
5. A Retrospective Study of Patients with Psoriasis Treated with Biologics: Relation to Body Mass Index and Gender.
Salah LA; Gillstedt M; Osmancevic A
Acta Derm Venereol; 2016 Nov; 96(7):974-975. PubMed ID: 27120180
[No Abstract] [Full Text] [Related]
6. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
Strober BE; Bissonnette R; Fiorentino D; Kimball AB; Naldi L; Shear NH; Goyal K; Fakharzadeh S; Calabro S; Langholff W; You Y; Galindo C; Lee S; Lebwohl MG
J Am Acad Dermatol; 2016 May; 74(5):851-61.e4. PubMed ID: 26853180
[TBL] [Abstract][Full Text] [Related]
7. Switching biologics in severe pediatric psoriasis: a retrospective analysis.
Ramos Pinheiro R; Diamantino F; Cabete J; Brasileiro A; Baptista J; Lopes MJP
Int J Dermatol; 2017 Dec; 56(12):1461-1464. PubMed ID: 28960270
[No Abstract] [Full Text] [Related]
8. Survival rates of biological therapies for psoriasis treatment in real-world clinical practice: A Canadian multicentre retrospective study.
Marinas JE; Kim WB; Shahbaz A; Qiang JK; Greaves S; Yeung J
Australas J Dermatol; 2018 Feb; 59(1):e11-e14. PubMed ID: 27858976
[TBL] [Abstract][Full Text] [Related]
9. A retrospective observational study on biological drug treatment in a daily practice serving patients with psoriasis in Japan.
Ohata C; Ohyama B; Nanri A; Shintani T; Nakama T
J Dermatolog Treat; 2019 Feb; 30(1):45-48. PubMed ID: 29676591
[TBL] [Abstract][Full Text] [Related]
10. Efficacies of biological therapies at week 12 in patients with plaque psoriasis in real-world academic clinical practice: a Canadian multicentre retrospective study.
Shahbaz A; Qiang J; Marinas JEC; Kim WB; Greaves S; Yeung J
Br J Dermatol; 2017 Jul; 177(1):297-298. PubMed ID: 27639251
[No Abstract] [Full Text] [Related]
11. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
Phan C; Beauchet A; Burztejn AC; Severino-Freire M; Barbarot S; Girard C; Lasek A; Reguiai Z; Hadj-Rabia S; Abasq C; Brenaut E; Droitcourt C; Perrussel M; Mallet S; Phan A; Lacour JP; Khemis A; Bourrat E; Chaby G; Deborde R; Plantin P; Maruani A; Piram M; Maccari F; Fougerousse AC; Kupfer-Bessaguet I; Balguérie X; Barthelemy H; Martin L; Quiles-Tsimaratos N; Mery-Brossard L; Pallure V; Lons-Danic D; Bouilly-Auvray D; Beylot-Barry M; Puzenat E; Aubin F; Mahé E; ;
J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1984-1992. PubMed ID: 30883928
[TBL] [Abstract][Full Text] [Related]
12. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
13. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
Wu N; Lee YC; Shah N; Harrison DJ
Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
[TBL] [Abstract][Full Text] [Related]
14. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Warren RB; Smith CH; Yiu ZZN; Ashcroft DM; Barker JNWN; Burden AD; Lunt M; McElhone K; Ormerod AD; Owen CM; Reynolds NJ; Griffiths CEM
J Invest Dermatol; 2015 Nov; 135(11):2632-2640. PubMed ID: 26053050
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.
Sator P; Richter L; Saxinger W; Vasiljevic M; Stingl G
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1742-9. PubMed ID: 25665143
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
[TBL] [Abstract][Full Text] [Related]
17. Implementing therapeutic goals in maintenance treatment of psoriasis with biologics: adalimumab can be more cost-effective than infliximab or ustekinumab in real life.
Puig L; Morales-Múnera CE
Eur J Dermatol; 2013; 23(3):407-8. PubMed ID: 23782978
[No Abstract] [Full Text] [Related]
18. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
[TBL] [Abstract][Full Text] [Related]
19. The Presence of HLA-A Bw4-80I KIR Ligands Could Predict "Difficult-to-Treat" Psoriasis and Poor Response to Etanercept.
Guarene M; Pasi A; Bolcato V; Cananzi R; Piccolo A; Sbarsi I; Klersy C; Cacciatore R; Brazzelli V
Mol Diagn Ther; 2018 Aug; 22(4):471-474. PubMed ID: 29943154
[TBL] [Abstract][Full Text] [Related]
20. Model for assessing the efficiency of biologic drugs in the treatment of moderate to severe psoriasis for one year in clinical practice in Spain.
Puig L; López-Ferrer A; Vilarrasa E; García I; Fernández-del Olmo R
Actas Dermosifiliogr; 2016; 107(1):34-43. PubMed ID: 26365029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
